Plain-English translation of NCT07204132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to treating high-risk bladder cancer that combines three treatments: surgical removal of the tumor, freezing the tumor base with liquid nitrogen (cryoablation), and then giving anti-PD-1 immunotherapy medications like Camrelizumab or Tislelizumab. The goal is to destroy cancer cells more effectively while keeping your bladder instead of removing it surgically.
Current bladder cancer treatments either remove the entire bladder—which causes serious complications and affects quality of life—or use other approaches that have high rates of cancer returning. This trial is exploring whether combining freezing technology with immune therapy could offer a better option that destroys cancer more effectively while preserving your bladder.
You likely qualify if…
You likely don't qualify if…
You will receive anesthesia and undergo a procedure where doctors remove your tumor through the urethra using a camera, then apply freezing treatment to the tumor base (at least two freeze-thaw cycles of 3–5 minutes each). After recovery, you will receive immune therapy injections based on your tumor's pathology results. The study runs from July 2025 to July 2027, and your treatment will include follow-up visits to monitor your response and check for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China